Modification of pyrimidine derivatives from antiviral agents to antitumor agents

Anticancer Research

Volumn 26, Issue 1 A, 2006, Pages 91-97

  Kimura, Hiroyuki ^a   Katoh, Takahiro ^a   Kajimoto, Tetsuya ^a   Node, Manabu ^a   Hisaki, Masakatsu ^b   Sugimoto, Yoshikazu ^c   Majima, Tetsuo ^c   Uehara, Yoshimasa ^d   Yamori, Takao ^c  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b Azwell Inc   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Antitumor agents; Antiviral agents; Pyrimidine derivatives

Indexed keywords

2,4 DIAMINOPYRIMIDINE DERIVATIVE; ALCOHOL DERIVATIVE; ALKYL GROUP; AMINE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOBUTANE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GLYCOPROTEIN P; METHYL GROUP; PHENYL GROUP; PHOSPHATE; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; ESTERIFICATION; HUMAN; HUMAN CELL; LEUKEMIA P 388; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CELL LINE; CELL LINE, TUMOR; DOGS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LEUKEMIA P388; P-GLYCOPROTEIN; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 32144437830     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Hisashi M, Imabori H, Azuma M, Suzutani T, Iwakura F, Ohta Y, Kawanishi K, Ichigobara Y, Node M, Nishide K, Yoshida I and Ogasawara M: Antiviral Res 42: 121-137, 1999.
2. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrichi M, Campbell H, Mayo J and Boyd M: J Natl Cancer Inst 83: 757, 1991.
3. Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K, Mita I, Edatsugi H, Matsuba Y, Takezawa K, Nakanishi O, Kohno H, Nakajima Y, Komatsu H, Andoh T and Tsuruno T: Cancer Res 59: 4042-4049, 1999.
4. Dan S, Tsudano T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y and Yamori T: Cancer Res 62: 1139-1147, 2002.
5. Dan S, Shirakawa M, Mukai Y et al: Cancer Sci 94: 1074, 2003.
6. Yamori T: Cancer Chemother Pharmacol 52: S74-S79, 2003.
7. Nakatsu N, Yoshida Y, Yamazaki K, Nakamura T, Dan S, Fukui Y and Yamori T: Mol Cancer Ther 4: 399-412, 2005.
8. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J and Boyd MR: J Natl Cancer Inst 81: 1088, 1989.
9. Fukazawa H, Li P-M, Mizuno S and Uehara Y: Anal Biochem 212: 106-110, 1993.
10. Li P-M, Fukazawa H, Mizuno S and Uehara Y: Anticancer Res 13: 1957-1964, 1993.
11. Hanai N, Nores G, Torres-Mendez C and Hakomori S: Biochem Biophys Res Comm 147: 127-134, 1987.
12. Bertics PJ and Gill GN: J Biol Chem 260: 14642-14647, 1985.
13. Sawano A, Takahashi T, Yamaguchi S and Shibuya M: Biochem Biophys Res Commun 238: 487, 1997.
14. Broxterman HJ, Kuiper CM, Schuurhuis GJ, Tsuruo T, Pinedo HM and Lankelma J: Biochem Pharmacology 37: 2389, 1988.
15. Rogan AM, Hamilton TC, Young RC, Klecker RW and Ozols RF: Science 224: 994, 1984.
16. Broxterman HJ, Kuiper CM, Schuurhuis GJ, Van der Hoeven JJM and Pinedo HM: J Lankelma, Cancer Lett 35: 87, 1987.
17. Leyva A, Appel H and Pinedo HM: Leukemia Res 6: 483, 1982.